S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:HRTX - Heron Therapeutics Stock Price, Forecast & News

$25.59
-0.10 (-0.39 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$25.40
Now: $25.59
$25.90
50-Day Range
$18.70
MA: $22.78
$26.61
52-Week Range
$15.68
Now: $25.59
$28.70
Volume39,670 shs
Average Volume987,807 shs
Market Capitalization$2.30 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HRTX
CUSIPN/A
Phone858-251-4400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$77.47 million
Book Value$4.74 per share

Profitability

Net Income$-178,840,000.00
Net Margins-140.55%

Miscellaneous

Employees198
Market Cap$2.30 billion
Next Earnings Date2/28/2020 (Estimated)
OptionableOptionable

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.


Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics Inc (NASDAQ:HRTX) issued its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.15. The biotechnology company earned $42.62 million during the quarter, compared to analysts' expectations of $34.02 million. Heron Therapeutics had a negative net margin of 140.55% and a negative return on equity of 60.76%. The business's quarterly revenue was up 115.4% on a year-over-year basis. During the same period last year, the business earned ($0.49) EPS. View Heron Therapeutics' Earnings History.

When is Heron Therapeutics' next earnings date?

Heron Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, February 28th 2020. View Earnings Estimates for Heron Therapeutics.

What price target have analysts set for HRTX?

8 Wall Street analysts have issued twelve-month target prices for Heron Therapeutics' stock. Their forecasts range from $32.00 to $75.00. On average, they expect Heron Therapeutics' share price to reach $49.43 in the next twelve months. This suggests a possible upside of 93.2% from the stock's current price. View Analyst Price Targets for Heron Therapeutics.

What is the consensus analysts' recommendation for Heron Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heron Therapeutics.

What are Wall Street analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:
  • 1. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (11/15/2019)
  • 2. Evercore ISI analysts commented, "We remain highly constructive on the name as ‘011’s differentiated product profile and today’s opioid awareness environment should help propel adoption of the product in a wide range of surgical procedures. We’ve updated the model following earnings; PT remains $75 (OP).  HRTX is confident that the answers to the FDA’s CRL are readily addressed. We will likely see a press release after the NDA is refiled, and the company plans to request a Type A meeting. The key dislocation: the company’s ‘011 timelines have reset, but the commercial opportunity remains unchanged. With the stock trading at these levels, we continue to see substantial upside if the company can execute its launch strategy." (8/13/2019)
  • 3. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and $38 target price on HRTX shares after the company reported a nice sales beat driven by Cinvanti and provided a incremental update indicating it plans to meet with the FDA shortly" to discuss the responses to the CRL it received in May for HTX-011. We remain positive on HTX-011’s approvability as a local, non-opioid analgesic and given the low visibility into the company’s CRL resolution process, we think today’s update could suggest we are nearing a more material one on this front. We continue to view this as the company’s key upcoming catalyst." (8/5/2019)
  • 4. Northland Securities analysts commented, "We believe these requirements are addressable, and anticipate resubmission prior to YE19, w/ approval in late-1H2020 or earlier. Heron Therapeutics reported 2Q results, with topline results beating expectations and EPS aligned with consensus. Product sales totaled $36.7MM, vs. our forecast of $32.3MM and the consensus of $31.8MM, respectively. Topline results reflected continued strength of CINVANTI, which posted sales of $33.2MM vs. our forecast of $28.5MM. CINVANTI sales advanced significantly sequentially from $28.0MM. SUSTOL sales were flat at $3.5MM, reflecting continued pressure from arbitrage relating to generic entry of palonestron. Importantly, Heron reiterated full-year product sales guidance of $115MM-to-$120MM. Operating loss and EPS were aligned with our expectations at ($51.8MM) and ($0.63), respectively." (8/5/2019)
  • 5. Cowen Inc analysts commented, ": Post 1Q19, we are reiterating our Overweight rating and $18 PT on CHMA. We believe the stock continues to trade at a significant discount to its potential intrinsic value. We believe the risk-reward going into Phase 3 data for Mycapssa (oral octreotide) for the treatment of acromegaly, to be released in 3Q19, remains positive. As the company advances Mycapssa toward approval, we expect data readouts, approvals, and upward earnings revisions to drive CHMA’s stock higher." (5/9/2019)

Has Heron Therapeutics been receiving favorable news coverage?

Media headlines about HRTX stock have trended positive on Wednesday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Heron Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Heron Therapeutics.

Who are some of Heron Therapeutics' key competitors?

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include bluebird bio (BLUE), Micron Technology (MU), Cara Therapeutics (CARA), Immunomedics (IMMU), Seattle Genetics (SGEN), Amarin (AMRN), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Gilead Sciences (GILD) and ImmunoGen (IMGN).

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the folowing people:
  • Dr. Barry D. Quart, Pres, CEO & Director (Age 62)
  • Mr. Robert E. Hoffman C.P.A., CPA, CFO & Sr. VP of Fin. (Age 53)
  • Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 59)
  • Mr. David L. Szekeres, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 45)
  • Mr. Sean T. Ristine, VP of HR (Age 49)

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (6.12%), State Street Corp (3.01%), Millennium Management LLC (0.63%), Great Lakes Advisors LLC (0.32%), Rosenblum Silverman Sutton S F Inc. CA (0.18%) and California Public Employees Retirement System (0.18%). Company insiders that own Heron Therapeutics stock include Barry D Quart, John Poyhonen, Kevin C Tang, Kimberly Manhard, Robert Hoffman, Robert Rosen and Waage Christian. View Institutional Ownership Trends for Heron Therapeutics.

Which institutional investors are selling Heron Therapeutics stock?

HRTX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Tang Capital Management LLC, Voloridge Investment Management LLC, Searle & CO., Great West Life Assurance Co. Can, Private Asset Management Inc., Oppenheimer & Co. Inc. and Rosenblum Silverman Sutton S F Inc. CA. View Insider Buying and Selling for Heron Therapeutics.

Which institutional investors are buying Heron Therapeutics stock?

HRTX stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Great Lakes Advisors LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Boston Advisors LLC, Russell Investments Group Ltd., Commonwealth Equity Services LLC and BB&T Securities LLC. Company insiders that have bought Heron Therapeutics stock in the last two years include Barry D Quart, John Poyhonen, Kevin C Tang and Waage Christian. View Insider Buying and Selling for Heron Therapeutics.

How do I buy shares of Heron Therapeutics?

Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $25.59.

How big of a company is Heron Therapeutics?

Heron Therapeutics has a market capitalization of $2.30 billion and generates $77.47 million in revenue each year. The biotechnology company earns $-178,840,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Heron Therapeutics employs 198 workers across the globe.View Additional Information About Heron Therapeutics.

What is Heron Therapeutics' official website?

The official website for Heron Therapeutics is http://www.herontx.com/.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]


MarketBeat Community Rating for Heron Therapeutics (NASDAQ HRTX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  577 (Vote Outperform)
Underperform Votes:  437 (Vote Underperform)
Total Votes:  1,014
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe HRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: Cash Asset Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel